Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea

NCT01154244 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1439

Last updated 2011-01-25

No results posted yet for this study

Summary

The purpose of this study is investigating the clinical characteristics of newly diagnosed, drug naïve type 2 diabetic patients according to insulin secretion and insulin resistance.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

OTHER

HOMA-IR

Blood sampling for HOMA-IR and HbA1C, fasting glucose, C-peptide, Lipid profile

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01154244 on ClinicalTrials.gov